Gene therapy holding pattern

While companies continue to pile onto the gene therapy bandwagon, a recent trend in clinical holds hints that new safety precautions could come into play.

In the last 20 months, six clinical holds have been placed on five different gene therapies, most of which are in development for Duchenne muscular dystrophy (DMD). Three were held for safety issues, two of which were DMD therapies targeting muscle (see Table: “Gene Therapy on Hold”)...